Tender investigation of Dongbao in Anhui Province in 7-1 Chinese Tonghua

From the end of last year to date, Anhui Province, the basic drug replenishment of the Central Tender procurement, participated in the Dongbao of Tonghua (600867.　　SH) almost failed miserably. The policy adopted by centralized bidding and purchasing of basic drugs in Anhui Province was previously considered to have achieved "significant institutional innovation".　　This adopted a double envelope bidding, price-linked, a single source of commitment, production enterprises to undertake the distribution of responsibility and many other new measures of the program, was summed up as "Anhui model", and is expected to be promoted nationwide.　　The daily economic news reporter notes that Tonghua Dongbao, which has the largest recombinant human insulin production base in Asia, is folding the "Anhui model". In Anhui unique "double Envelope system tender" (that is, the first assessment of technical standards, re-evaluation of Business Standard mode), Tonghua Dongbao although in the cast of the 7 dosage forms are cast a minimum price, but 6 of the dosage forms because failed to pass the technical standard assessment, directly lost the opportunity to enter the business and the final bid.　　At the same time, foreign drug companies Lilly, Connaught and Connaught, Bayer and so on has become a big winner. "It's unreasonable. "Tonghua Dongbao, a related person in the daily economic news reporter in the" personal name, "the opinion.　　But the reporter learned in the interview, for the most controversial technical standard set to the company's overall sales amount as a measure of the practice, Anhui Province, the head of the Procurement Service center of Medicine, said this is because there is no single product authoritative sales data can be measured, tender to achieve quality, reasonable price.　　Industry insiders pointed out that for the "accidental out", Tonghua Dongbao should more consider why it will be in the first round of technical target will be eliminated, investigate the reasons for this.　　"Anhui mode" "double envelope" system is undoubtedly the core of "Anhui mode".　　According to the "Daily economic news" obtained by the "primary medical and health institutions in Anhui Province, the basic drug supplement drugs centralized tender procurement Implementation Scheme (2010 edition)" introduced, the overall goal of the program is "to ensure drug quality, control the high price of drugs, standardize the purchase and sale behavior." In the specific tendering method, in the principle of insisting on the quality priority and reasonable price, the paper adopts the technology standard and Business standard "double envelope" method to open the tender, implement (quality type) Single sourcing, "ensure that the enterprise obtains all market share of the quality type drug in the winning region",　　That means that the successful bidder will take the provincial government-owned primary medical and health institutions and integrated management of the administrative Village health Room of the relevant drug market share.　　A large number of pharmaceutical companies decided to participate in the bidding, only the insulin-related specifications category, attracted including Tonghua Dongbao, Zhuhai Federation, Lilly, Connaught and Connaught and other domestic and foreign drug companies.　　According to the provisions of Anhui Province, pharmaceutical production enterprises can directly bid, while the production enterprises set up only the sale of the company's drugs, commercial companies, the domestic distributor of imported drugs also as the production enterprises. In Anhui's unique "double envelope" mode, the above companies need to first pass the technical standard of the review, then to get into the business price parity opportunities. According to the plan of Anhui, technical standard review will be based on the packageIncluding quality type, production scale, sales, industry rankings, market reputation, bad records and other related indicators, the implementation of hundred evaluation.　　The rules show that the technical standard is judged according to the score, identify the drugs to enter the evaluation of business standards, such as when the shortlisted technology standard drugs in 3 to 4, then 2 of them into the business Standard assessment; When the number of drugs approved by the technical standard to reach 5 to 6, then 3 pharmaceutical companies can enter the Business Standard review. In the next phase of business evaluation, "in principle, the lowest quotation to determine the intended acceptance of drugs."　　This also means that once the enterprise through the technical standards of the evaluation finalists to the Business Standard review, the basic will follow the low bidder's approach.　　The low-cost bidder Tonghua Dongbao Tonghua Dongbao pursues is the low price advance strategy. December 27, 2010, Anhui Province Medicine centralized procurement platform announced the "primary medical and health institutions in Anhui Province, the basic drug supplement drugs centralized tender for the purchase of commercial bids bid publicity."　　"Daily economic news" After the statistics found that Tonghua Dongbao in the participation of the 7 kinds of specifications of the bid, have cast a minimum price. If the specification is 3ml:300iu (refill), the general name "50/50 mixed recombinant human insulin injection", the price of Tonghua Dongbao is 51.50 yuan.　　The other 6 products, Tonghua Dongbao price is 45.20 yuan.　　In these categories of drugs, the Zhuhai Federation in the specification 3ml:300iu Universal name "Protamine recombinant human insulin injection," the product cast a price of 49.17 yuan.　　Lilly to Suzhou Pharmaceutical Co., Ltd. (hereinafter referred to Suzhou) in the specifications 3ML:300IU universal name "Protein recombinant human insulin injection," the product cast 55.80 yuan; in the specification 3ml:300iu (refill) general name "recombinant human insulin injection" cast a price of 55.40 yuan.　　Connaught and Connaught (China) Pharmaceutical Co., Ltd. in the specification 10ML:400IU generic name "sperm protein biosynthesis human insulin" injection, the price of 55.90 yuan.　　Bayer Medical Care Co., Ltd. in the specification 3ml:300iu Universal name "Protamine recombinant human insulin injection", and specification 3ml:300iu (refill) general name "recombinant human insulin injection" in the quotation are 53.92 yuan.　　Companies turned out of the hole, Tonghua Dongbao in a number of bids for the lowest price, which let many of the company's investors are excited, and thought that Tonghua Dongbao successfully passed the technical standard assessment, will win Anhui Big single.　　But that is not the case.　　In the 2 days after the price exposure of various pharmaceutical companies, December 29, 2010, Anhui Province, the procurement platform above the medical Center released the "on the publicity of primary medical institutions in Anhui Province, the basic drug replenishment of pharmaceutical products focused on the procurement of tender technology" notice. In the end, Tonghua Dongbao only "50/50 mixed recombinant human insulin injection" a product through the technical standard assessment, to obtain business standard price comparison opportunity, the other 6 products are in the technical standard review on the drubbing and return, directly lost with other pharmaceutical companies thanPrice. "Our quotation is very low, product quality is no problem, the present situation, only 1 insulin products can enter the Anhui market, it is too unreasonable." Tonghua Dongbao People told reporters.　　The remaining 6 products will be in Anhui Province 105 counties (city, district) and 3 Laboratories, 1263 Township Hospitals, 605 Community health Service centers and 10,750 Integrated management of the administrative village health room insulation. Technical standard set up dispute "Tonghua Dongbao almost annihilated, the result of the bidding is stunning.　　Xi ' an investor Rico told reporters. "This time according to Anhui province's stipulation, the winning enterprise will take Anhui all big hospitals, the primary medical health Organization, the Village Village health room market share, directly erodes the Tonghua Dongbao original main sales position."　　"Rico Analysis said. His other concern is: "Since the Anhui model is considered likely to be extended to the country, if the future bidding, Tonghua Dongbao insulin products are likely to always be defeated by foreign medicine." Why is there such a result? How are the terms in the bidding process set? "Another investor, Liang Lei, analyzed the possible reasons for the failure of Tonghua Dongbao:" In accordance with the provisions of the Anhui tender, in 3 to 4 companies bidding, the admission technology standard top 2 companies. Therefore, the technical standard setting method is very important. In the competition with foreign drug companies such as Eli Lai, Connaught and Connaught, Tonghua Dongbao may not be the dominant.　　"The reporter obtains" the Basic Medicine supplementary Medicine of the primary medical and health institution in Anhui Province (2010 edition) The related appendix, explained the technical standard evaluation standard in detail. Annex VI on the Technical standard assessment system explained that, according to the relevant provisions and implementation of the program, technical standard review of drug quality and reliability (Enterprise GMP qualification certification, quality type, production scale, sales, industry rankings, market reputation, bad records, etc.) related indicators, the implementation of hundred evaluation.　　Objective indicators of 88 points, subjective indicators 12 points. In the 88 Points of drug quality (i.e. objective index), the term "quality type" accounted for 50 points. Among them, such as a pharmaceutical enterprise "with our intellectual Property Office granted the validity of the compound Entity invention Patent Certificate of drugs", can be 50 points, such as "National approval of the original research category of individual pricing drugs, state secret prescriptions, Chinese medicine, the protection of the first class, Western medicine, biological products class,　　The quality of the national natural Science or scientific and technological progress Second prize and the award of drugs "can be 46 points; after that, according to the" Quality type ", the score gradually decreased, until the" General GMP drug "score of 36 points. Another account of the relatively heavy "sales amount", accounting for 20 points. The "Sales Amount" is based on the 2009 annual VAT tax report of the production enterprise, according to the corresponding sales amount of VAT.　　If the enterprise sales in 200 million yuan ~5 billion each increase of 100 million yuan 1 points, greater than 500 million yuan per increase of 100 million yuan 0.5 points, the highest 20 points. In addition, "industry platoon"The highest can also be 12 points." This is based on the national Ministry of Industry published 2009 years of Chemical medicine or proprietary Chinese medicine industrial enterprises, corporate units according to the main business income ranking based on the evaluation, the first to get 12 points, each of the lower back 0.03 points.　　In addition, "dosage form characteristics" and "reserve conditions" can be 1.5 points respectively, "raw material source" 2 points, "drug validity" 1 points. Subjective indicators of a total of 12 points, of which "clinical efficacy evaluation" a total of 4 points, by experts, mainly based on clinical evaluation of the outcome of the literature and clinical drug experience evaluation.　　In addition, "Brand awareness" has 4 points, "drug packaging quality and convenience and practical" and "protection of supply and accompanying services" can be 2 points respectively. "For 20 cents of the sales amount," Anhui is based on the overall sales amount of the enterprise, rather than the amount of sales of the drug to be recruited. Just imagine, if a company's other drugs sales are very large, but the amount of insulin products sales is very small, can also win the bid? Liang Lei said, "If Tonghua Dongbao find a large amount of sales of enterprises as agents, is not also able to win the bid?" The setting of the technical standard is unreasonable.　　The above-mentioned Tonghua Dongbao people also think. Authoritative response: Single goods sales cannot be "before the tender and no one to find us, reflecting the technical standard review settings There are problems." "Anhui Province pharmaceutical Centralized Procurement Service center, a relevant person in the daily economic news," said the interview. Xu Henqiu, deputy director of the provincial health department, also said: "We have a fair and impartial public bidding exercise." "And for investors to reflect the" such as the overall sales amount of the enterprise based on the single product sales, and the company's overall sales of less business unfair "problem, the drug Central Procurement Service center responsible told reporters:" We are indeed the size of the enterprise as part of the evaluation of technical standards. " Because as a single product, there is no single authoritative sales data to be measured, there is also a lack of objective measurement indicators. "The problem with Tonghua Dongbao, is mainly in the sales amount and the company ranked these two points lag behind."　　The official told reporters. The actual situation is also true, in Liang Lei view, because "Enterprise rank" item is according to "2009 Chemical medicine or proprietary Chinese medicine industrial enterprises, corporate units according to the main business income" as the basis of the calculation of the ranking, so for Tonghua Dongbao also have no advantage to say. Tonghua Dongbao 2009 Annual report shows that the company's operating income of 573 million yuan. Such income is not much in the pharmaceutical sector.　　The head of the center said frankly. "This may be the exception to the situation, just in the case of foreign companies, compared with these enterprises, Tonghua Dongbao in the company rankings and sales amount does not occupy an advantage." "Now I am afraid that no province can be developed according to a single breed (technical standard Review rules)." A single breed of sales data can only be said by the enterprise itself, it is difficult to verify. "The reporter in Anhui Province Medicine centralized Procurement Service center to see a copy of the center to report to the relevant departments of the sinksNewspaper materials show, to "30/7010ML:400IU insulin" products For example, Connaught and Connaught in the technical standard ranked first, Tonghua Dongbao because in the "Sales Amount" item on the backwardness of the Chinese medicines and so on and was eliminated; in "30/70 mixed recombinant human insulin 3ml:300iu" products, Leading drug companies for Connaught and Nord and Bayer, Tonghua Dongbao was ranked only fourth; on another product, the "Sales Amount" and "drug clinical efficacy" scored higher than Tonghua Dongbao in the other products; in the "3ml:300iu recombinant human Insulin" product, the Zhuhai Federation in "the sales Amount" and "the Enterprise Rank"　　Two of the leading rivals more than 20 points, the first successful finalists, a product, Tonghua Dongbao in the rest of the indicators are the same as the ceremony to Suzhou, the "Sales amount behind the other 3 points" and was excluded.　　Industry: Tonghua Dongbao should be more reflective of the controversy is another point is that squeezed out of Tonghua Dongbao the successful bidder, is considered to be a foreign high price medicine and Anhui local pharmaceutical companies. As early as July 2009, Bayer had signed an exclusive supply and distribution agreement with BIOTONS.A, the insulin maker of Poland, and the Bioton Company's branch SCIgen company in Singapore. "The contract and payment will ensure that Bayer has the exclusive right to operate the recombinant insulin product in China," the Bayer press release said at the time. "It is noteworthy that the information posted on the website of" International Hefei Economic and technological Development zone "shows that the Polish Bionton company invested in Hefei to establish a real bio-Pharmaceutical Co., Ltd., and another shareholder of the tournament is Hefei Local Enterprise" Hefei life Science and Technology Park Investment Development Co., Ltd. " Journalists have since tried to contact Bayer, but have not yet received a reply to the deadline.　　The general rules of the Hefei race are not clear, and they refuse to explain further. "We don't think it's possible that the so-called Bayer products are for the local business distribution of the Hefei game," he said. "Anhui Province Medicine centralized Purchasing service center" said the person in charge, "I have not even heard the name of the enterprise, which is not involved in local protectionism."　　"The above-mentioned center proposed to submit to the relevant departments of the reporting materials, the Bayer submitted the" Enterprise qualification and product information are Bayer Medical and Health Care Co., Ltd. 's own real, legal and effective documents, and said that Bayer is "independent pharmaceutical corporate participation in the bid." In addition, because of the import of the imported Egyptian Lilly products are also involved in the Anhui Province of the base drug bidding, resulting in higher drug prices situation, Lilly Pharmaceutical response to the reporter said "price is not the only factor." "Because the Lilly pharmaceutical did not get our country-level agency qualifications, so participate in the bidding to find a national level agent qualification of the agent, this operation has no irregularities." As in the pharmaceutical retail, at home and abroad, the drug prices of different enterprises, although the price is different, but the final option is still in the hands of consumers, domestic and foreign pharmaceutical companies have different advantages of products。 "Rdpac (China Foreign Investment Enterprise Association pharmaceutical Development and Development Industry Committee), a spokesman to the daily economic news reporter said, one of the patients known to have a patient who spends about 200 yuan a month on the use of Enoch's insulin, and if you use the insulin from the Tonghua Dongbao, it can be 70 cheaper. ~80 Yuan.　　Although the latter is more advantageous in price, different quality standards (human insulin and animal-derived insulin) and different injection methods have different effects on the effectiveness of insulin. "For this so-called Tonghua Dongbao's ' accidental exit ', I think the Tonghua Dongbao should consider more why it will be eliminated in the first round of technical target, investigate the reasons." In our opinion, the situation of foreign medicine and imported drugs has no effect on the bidding.　　"the spokesman said. "Now it looks like the bidding has been qualified and reasonably priced." "Anhui Province pharmaceutical centralized procurement platform related to the evaluation," of course, there are improvements in space, but it is difficult. ”